After administration of DC vaccines to HER2 positive DCIS and stage I breast cancer patients, substantial anti-HER2 Th1 immunity is induced (Figure 1), with pCR rates approaching 25%, with loss of the target antigen in the remainder of patients (Sharma et al., 2012; Datta et al., 2015b). Here, ERBB2 is linked to breast cancer.